Please try another search
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Dong-Joong Kim | 59 | 2014 | CFO, Executive VP, MD & Director |
Kyonghee Kim | 65 | 2020 | Independent Outside Director |
Changwoo Lee | 55 | - | Independent Director |
John Chongbo Rim | 63 | 2019 | CEO, President & Chairman of Board |
Geunnyeong Heo | 68 | 2019 | Independent Director |
Seoung Hwan Suh | - | 2024 | Independent Director |
Kun Lo | 61 | 2023 | Executive VP, Head of EPCV Center & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review